Genomic BRCA and Extensive ovArian Cancer Testing

ARCAGY/ GINECO GROUP1,500 enrolled

Overview

This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Epithelial Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient older than 18 years. * Patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014) * Patient in first line therapy * Available tumor sample fixed in formalin and included in paraffin (FFPE): * in pre-chemotherapy, insofar as possible * having a sufficient tumor surface, with a final cellularity of at least 20% * Identification of a molecular genetics' cancer platform participant in GREAT and an onco-geneticists team working with the investigator team * Patient consenting her data to be collected and submitted through an automated processing * Patient beneficiary from the French social security Exclusion Criteria: * Patient with a mucinous ovarian carcinoma * Patient pregnant or breastfeeding * Patient under legal protection (guardianship or court order) or unable to consent

Locations (137)

Outcomes

Primary Outcomes

Correlation between Progression Free Survival (PFS) and the detected tumor genetic abnormalities

Time frame: From baseline until the date of progression or death, which ever occurs earlier, assessed up to 10 years

Secondary Outcomes

Correlation between age and the detected tumor genetic abnormalities

Time frame: Baseline

Correlation between histology status and the detected tumor genetic abnormalities

Time frame: Baseline

Correlation between FIGO stage and the detected tumor genetic abnormalities

Time frame: Baseline

Correlation between surgery resection status and the detected tumor genetic abnormalities

Time frame: Up to 10 years

Correlation between treatment response and the detected tumor genetic abnormalities

Time frame: Up to 10 years

Correlation between Overall survival (OS) and the detected tumor genetic abnormalities

Time frame: From baseline to death, assessed up to 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Centre de Radiothérapie et d'Oncologie de Moyenne Garonne (CROMG)

Agen, France

Hôpital Privé d'Aix en Provence

Aix-en-Provence, France

Centre Hospitalier Général d'Aix-en-Provence

Aix-en-Provence, France

CHU Amiens

Amiens, France

Clinique Victor PAUCHET

Amiens, France

Institut de Cancérologie de l'Ouest - ICO

Angers, France

Hôpital Privé d'Antony - Ramsay Santé

Antony, France

CH Arras

Arras, France

CH Auxerre

Auxerre, France

Institut Sainte Catherine

Avignon, France

...and 127 more locations